A monthly snapshot of FDA activity involving therapies for the prevention and treatment of neurologic diseases.
A group of former Harvard athletes who are now physicians and scientists pitched the University’s sports medicine team last ...
Prolonged seizures led to work productivity loss and caused worrying and anxious/depressed feelings in patients with epilepsy ...
NeuroPace, Inc. , a medical device company focused on transforming the lives of people living with drug resistant epilepsy, today announced a major milestone in its clinical evidence program with the ...
Zacks Investment Research on MSN
Roche highlights Gazyva progress, reports data on Enspryng, MS drug
Roche RHHBY announced that the FDA has accepted its supplemental application for Gazyva/Gazyvaro (obinutuzumab) to treat ...
About ENSPRYNG® (satralizumab) ENSPRYNG, which was developed by Chugai, a member of the Roche Group, is a humanised monoclonal antibody that targets interleukin-6 (IL-6) receptor activity. ENSPRYNG ...
EPX-100, clemizole hydrochloride, is under development for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). EPX-100 acts by targeting central 5-hydroxytryptamine receptors to ...
A lifetime of mental stimulation—like reading, writing, and learning new skills—may help protect the brain as we age. People with the highest levels of cognitive enrichment had a much lower risk of ...
CARSON CITY, Nev., April 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and ...
UCB will present additional studies and data analyses highlighting UCB's ongoing commitment to improving outcomes for people living with gMG Two studies assessed the bioequivalence and effectiveness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results